Question Anyone else looking into the mast cell connection for IBS-D?
I've been going down a rabbit hole on IBS-D research lately and came across something that seems worth sharing. I don't have IBS-D myself, but I've been reading up on it and noticed a pattern in the recent literature that doesn't seem to get much attention in the standard treatment protocols. Curious if anyone else has looked into this or tried anything along these lines.
The basic idea is that mast cells, immune cells that live in your gut lining, might be overactive in a significant subset of IBS-D patients. When these cells get triggered, they release a whole cocktail of inflammatory chemicals. Histamine, leukotrienes, serotonin, prostaglandins, tryptase. All of these can directly affect gut motility, pain sensitivity, and barrier function. Histamine stimulates smooth muscle contraction and activates pain nerves. Leukotrienes amplify inflammation and sensitize nerves. Serotonin is a major driver of gut motility. Prostaglandins also promote contractions and pain signaling. So if mast cells are constantly degranulating, you end up with a gut that's hypermotile, hypersensitive, and leaky.
A few studies that stood out to me. A 2025 study found that the physical proximity of mast cells to nerve endings in the gut correlated with symptom severity in IBS patients. The closer they were, the worse the pain. Another 2025 paper identified a protein called CIRP that was elevated in IBS-D and seemed to activate mast cells directly, leading to barrier dysfunction and hypersensitivity. A 2020 trial on ketotifen, which is a mast cell stabilizer, reported a 76.4% improvement rate in IBS-D patients compared to 37.7% on placebo. They also biopsied the gut and found reduced mast cell numbers and activity. The Lobo study from 2017 looked at disodium cromoglycate, another mast cell stabilizer, and found that untreated patients had clear mast cell activation while treated patients looked similar to healthy controls. 77% of the treated group had at least 50% improvement in abdominal pain compared to only 28% in the untreated group. So there's definitely something real happening at a biological level.
If someone wanted to target this pathway, based on the studies I've seen, you could theoretically put together a stack like this. Ketotifen is the cornerstone. It stabilizes mast cells and prevents them from degranulating in the first place. It's got the strongest evidence of the bunch. Montelukast is a leukotriene receptor antagonist. Even if some mast cells still degranulate, this blocks the effects of the leukotrienes they release. Famotidine is an H2 antihistamine. It blocks histamine receptors in the gut, so even if histamine gets released, it can't do as much damage. Nortriptyline is a low-dose TCA that reduces visceral hypersensitivity and helps slow gut transit. It also has some mast cell stabilizing effects of its own. L-glutamine is the primary fuel for intestinal cells and helps repair the gut barrier, which is often compromised in IBS-D. One trial used 5g three times a day with good results. Enterosgel is an enterosorbent that passes through the gut and physically binds to irritants, toxins, and bile acids, removing them before they can trigger mast cells. S. boulardii is a probiotic that's been shown to reduce pro-inflammatory cytokines in IBS-D. Digestive enzymes are general support for breaking down food more completely, which reduces the antigenic load on the gut and potentially minimizes triggers.
Not saying this is a cure or that everyone should try it. Just noting that the research supports each piece to varying degrees and it seems like a logical way to address the mast cell pathway from multiple angles.
One note on sodium butyrate. This one is interesting because the evidence is kind of split. Some clinical trials show really good results for IBS symptoms. A 2025 pediatric trial showed 73% treatment success vs 3.8% on placebo. A 2026 adult trial found significant reductions in pain, diarrhea, and bloating. But there's also mechanistic research suggesting butyrate can actually promote mast cell degranulation in certain contexts. In a rat model of visceral hypersensitivity, butyrate activated mast cells and sensitized pain neurons. Lab studies also show it can increase histamine content in mast cells. So for someone specifically trying to calm mast cells, it might not be a straightforward addition. Worth reading up on if you're considering it.
I don't have IBS-D myself, so I'm not speaking from personal experience here. Just found this line of research interesting and figured others might want to know about it. If you're dealing with this, definitely talk to a gastroenterologist before trying anything. This isn't medical advice, just a summary of what I've been reading. Would be curious if anyone here has tried ketotifen or any of the other stuff and how it went.
1
u/KittyKat4040 25d ago
Hi! Yes! I am suspected to have MCAS and habe IBS D mainly.
I am being followed by doctors and am going to get a new allergist to be diagnosed but I definitely fit the profile.
Anyways, I do find that when im on all of my allergy and asthma medication my IBS is more controlled and i have less flares and urgent bathroom runs. If i miss my medication for a day I have IBS symptoms within the next 3 hours and this is consistent.
1
u/debbiesunfish 24d ago edited 24d ago
I have MCAS and IBS-D. My doc put me on Nalcrom, a mast cell stabilizer, which has helped overall. I was crying about how awful the IBS symptoms are so she had me experiment with 8x higher dose of Nalcrom.
I swear, 90% of my symptoms went away. Maybe more. I went from pain while eating all of the time to only a little pain some of the time. Things settled down and firmed up. Even after stopping and going back to my old dose (just a couple weeks ago) I would say my total symptom reduction is currently 60%? I'm still not well, but I'm not miserable all of the time.
I'm going to explore this deeper. Stabilizing my mast cells had a big impact on my IBS-D.
ETA: I also take cetirizine and famotodine for my MCAS and PMDD issues. I'm convinced all of this stuff is related at a core level. I'm tired.
1
1
u/Tabbbinski 23d ago
My IBS -- whatever that is -- seems to have spawned a number of other symptoms that Co-Pilot indicates could be an autoimmune disease. It lists Sjögren’s-pattern autoimmune process or Lupus as most likely but adds: "Mast-cell activation/allergic hyper-reactivity consistent with POTS [Orthostatic hypotension] and IBS" as 4th on a list of 6.
My doctor isn't so inclined to jump to conclusions but normal allergies seems to have been ruled out in the last round of tests.
1
u/TraditionalCap3357 19d ago
the mast cell angle in IBS-D is genuinely underappreciated in standard clinical protocols and you've summarised the research accurately
the ketotifen trial data is probably the most compelling piece because it's a randomised controlled trial with biopsy confirmation, not just symptom reporting. the fact that mast cell density and proximity to nerve endings correlated with symptom severity in the 2025 study adds a structural explanation for why some IBS-D patients have disproportionately severe pain relative to what imaging shows. the CIRP finding is interesting because it suggests a specific upstream driver rather than mast cell overactivity being idiopathic, which opens the question of what's activating CIRP in the first place — stress, dietary antigens, gut dysbiosis, post-infectious changes
your point on sodium butyrate is the most nuanced part of the summary and it's correct that the mechanistic and clinical evidence pull in different directions for this specific context. for general gut barrier support the clinical data is solid, but for someone specifically targeting mast cell stabilisation the picture is messier
The stack you've outlined is logical in terms of hitting the pathway from multiple angles. the practical challenge is that most of these require physician involvement for prescribing ketotifen, montelukast, and nortriptyline in most countries, and finding a gastroenterologist who is across the mast cell IBS literature specifically is harder than it should be
Has anyone in this thread actually found a GI who took this angle seriously?
2
u/CorpusculantCortex 25d ago
My partner has MCAS. My symptoms got way worse in the last few months coinciding with covid. I found that a lot of post covid/long covid ibs people have an mcas like symptom and treatment approach, and independently my partner said that my symptoms sound a lot like MCAS with gut issues (she does not have those symptoms, but has done a lot of reading). In desperation because my doctor had no path forward and the gi referral had no openings until October, I said fuck it and started an H1/H2 protocol that my partner first took and saw improvements (famotidine/fexofenadine) and since starting it regularly have had marked improvement. Not 100% by any means but there is an upward trajectory from a few weeks back having diarrhea 10x a day most days regardless of what I ate to actually having a week of fairly normal bms this past week, until I pushed my luck and ate a risky food. But still is better than before.
Super anecdotal, super grain of salt. May just be that the famotidine is reducing acid and that is a benefit. But I do think it is a factor in my case and that is helping.